Registry of Acute Coronary Syndrome From University Hospital of Vigo (CardioCHUVI)

September 7, 2018 updated by: Hospital Álvaro Cunqueiro

Registry of Patients Admitted by Acute Coronary Syndrome to University Hospital of Vigo

CardoCHUVI registry was aim to study ischemic and bleeding complication after an acute coronary syndrome (ACS), both in-hospital and follow-up events.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

CardioCHUVI is a retrospective study aim to analyze all consecutively patients admitted by acute coronary syndrome to University Hospital Alvaro Cunqueiro of Vigo, between January 2010 to January 2018

The objective of the project was to study cardiac and bleeding complications, such as reinfarction, heart failure, atrial fibrillation, stroke, and bleeding events, together with all-cause and cardiac mortality

Study Type

Observational

Enrollment (Anticipated)

8000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
    • Pontevedra
      • Vigo, Pontevedra, Spain, 36312

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Consecutive patients admitted by acute coronary syndrome in the University Hospital Alvaro Cunqueiro of Vigo between January 2010 to January 2018

Description

Inclusion Criteria:

  • Any patient admitted to University Hospital Alvaro Cunqueiro of Vigo for acute coronary syndrome.

Exclusion Criteria:

  • Secondary acute coronary syndromes during a hospital admission for another cause (i.e. acute myocardial infarction in the context of a sepsis)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All cause mortality
Time Frame: Through study completion, an average of 3 years
Death for any cause
Through study completion, an average of 3 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reinfarction
Time Frame: Through study completion, an average of 3 years
New spontaneous acute myocardial infarction
Through study completion, an average of 3 years
Bleeding
Time Frame: Through study completion, an average of 3 years
Any bleeding according to BARC definition (from 1 to 5)
Through study completion, an average of 3 years
Ischemic stroke
Time Frame: Through study completion, an average of 3 years
Ischemic stroke documented in CT
Through study completion, an average of 3 years
Cancer
Time Frame: Through study completion, an average of 3 years
Any type of malignant cancer
Through study completion, an average of 3 years
Heart Failure
Time Frame: Through study completion, an average of 3 years
Heart Failure admissions
Through study completion, an average of 3 years
Atrial Fibrillation
Time Frame: Through study completion, an average of 3 years
Atrial fibrillation documented in ECG
Through study completion, an average of 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital Álvaro Cunqueiro

Investigators

  • Study Chair: Emad Abu-Assi, MD, PhD, University Hospital Alvaro Cunqueiro, Vigo, Spain
  • Principal Investigator: Sergio Raposeiras-Roubín, MD, PhD, University Hospital Alvaro Cunqueiro, Vigo, Spain
  • Study Director: Andres Iñiguez-Romo, MD, PhD, University Hospital Alvaro Cunqueiro, Vigo, Spain

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2016

Primary Completion (Actual)

September 6, 2018

Study Completion (Anticipated)

February 1, 2020

Study Registration Dates

First Submitted

September 6, 2018

First Submitted That Met QC Criteria

September 7, 2018

First Posted (Actual)

September 10, 2018

Study Record Updates

Last Update Posted (Actual)

September 10, 2018

Last Update Submitted That Met QC Criteria

September 7, 2018

Last Verified

September 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Hospital Alvaro Cunqueiro

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Registry of all consecutive patients admitted by acute coronary syndrome (ACS) to an university hospital in order to analyze bleeding and ischemic complications according to the type and duration of dual antiplatelet therapy

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Coronary Syndrome

Clinical Trials on Dual antiplatelet therapy with ticagrelor/prasuglre

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe